BIOMEDICAL SEALANT MARKET ANALYSIS

Market Challenges And Opportunities

Biomedical Sealant Market Drivers:-

Approval of new biomedical sealants in key regions such as Europe is expected to drive growth of the biomedical sealant market. For instance, in 2017, Starch Medical, marketer and manufacturer of polysaccharide-based hemostatic products such as biomedical sealants was approved by C.E. Mark for Super Clot. Post the approval, company has planned to utilize their existing network of distribution partners along with their new strategic partners to bring Super Clot to hospitals and surgical teams throughout Europe. This strategic planning of product distribution is expected to fuel growth of the global biomedical sealant market.

Mergers and acquisitions by key players is also another factor expected to support the global biomedical sealant market growth. For instance, in January 2018, Baxter International Inc., a U.S.-based healthcare company, acquired two surgical products i.e. Recothrom and Preveleak of Mallinckrodt Pharmaceuticals—a producer of specialty pharmaceutical products. Recothrom is a thrombin based topical product, which is designed to assist hemostasis, this product is used when surgical methods to prevent flow of blood is ineffective in adults and pediatrics. Preveleak is a surgical sealant used to close suture holes to obtain hemostasis during surgical vascular reconstructions.

Non-availability of one sealants, which provide stiffness, elasticity, and high adhesion together, is a major restraining factor for growth of the market. For instance, though fibrin-based sealants do offer good elasticity, these offer low stiffness and adhesion. Cyanoacrylates have high adhesion and stiffness, however, offer low elasticity. These factors could negatively impact growth of the market over the forecast period.